semaj83/ctmatch_classification huggingface dataset:
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Patients who have signed Informed Consent Form prior to initiation of any study-related procedure Male and female adults aged ≥ 40 years Patients with moderate to severe airflow obstruction with stable COPD (Stage 2 or Stage 3) according to the 2014 GOLD Guidelines Patients with a post-bronchodilator FEV1 ≥40 and < 80% of the predicted normal value, and post-bronchodilator FEV1/FVC < 0.70 at run-in Visit 101. (Post refers to 15 min after inhalation of 400 µg of salbutamol) Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack /day x 10 years, or ½ pack/day x 20 years). An ex-smoker is defined as a patient who has not smoked for ≥ 6 months at screening Patients who are on triple treatment at least for the last 6 months (LAMA +LABA/ICS)  Patients who have not achieved acceptable spirometry results at Visit 101 in accordance with ATS (American Thoracic Society)/ERS (European Respiratory Society) for acceptability (one retest may be performed for patients that don't meet the acceptability criteria)  Patients who have had more than one COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the last year prior to Visit 1 Patients who developed a COPD exacerbation of any severity either 6 weeks before the screening (Visit 1) or between screening (Visit 1) and treatment (Visit 201) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation Other protocol-defined inclusion/
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Cytomegalovirus Retinitis HIV Infections Concurrent Medication Allowed Topical anti-Herpesvirus agents Zidovudine (AZT) for patients in deferral or foscarnet treatment groups mg every 4 hours. For patients on ganciclovir mg every 8 hours Dideoxyinosine (ddI) and other antiretroviral available via expanded access programs, investigational triazoles, granulocyte-macrophage colony-stimulating factor, and erythropoietin to treat marrow toxicity. The use of other investigational drugs will be considered on a drug by drug basis It is not recommended that patients receiving ganciclovir take AZT simultaneously. If AZT is prescribed for patients taking ganciclovir, it should be prescribed at reduced doses and discontinued if hematologic toxicity develops Patients must have Diagnosis of AIDS by CDC or a documented HIV infection  Co-existing Condition Patients with the following conditions or symptoms are excluded Sufficient media opacities to preclude fundus photographs in both eyes Concurrent Medication Excluded Other systemic treatments for Herpesvirus infections Other anti-cytomegalovirus therapy Excluded with foscarnet Parenteral pentamidine, amphotericin B, or aminoglycosides Use of marrow toxic agents with ganciclovir and nephrotoxic agents with foscarnet is discouraged, and alternative treatment should be used whenever possible
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-65.0,  Cytomegalovirus Retinitis HIV Infections Concurrent Medication Allowed Zidovudine (AZT) 8/90 Other available antiretroviral therapy Pneumocystis carinii pneumonia (PCP) prophylaxis, either systemic or local (aerosolized) Chemotherapy for Kaposi's sarcoma Systemic therapy for intercurrent opportunistic infections Acyclovir or other treatment of Herpes simplex virus (HSV) or Varicella zoster virus (VZV) infections Systemic therapy deemed necessary for appropriate medical management Patients must have AIDS and cytomegalovirus (CMV) retinitis in at least one eye, diagnosed by an ophthalmologist and verified by fundoscopy and fundus photography  Co-existing Condition Patients with the following are excluded Contraindication to intravitreal injection, including obvious external infection and vitreous hemorrhage Medical opacities of cornea, lens, and/or vitreous which precludes fundus photography Concurrent Medication Excluded Prophylactic acyclovir at time of study entry Other anticytomegalovirus (CMV) therapy, particularly systemic ganciclovir, foscarnet, or CMV hyperimmune globulin Topical ophthalmic medications should be avoided Cytomegalovirus (CMV) therapies and chronic acyclovir, including necessary therapies for an intercurrent opportunistic infection
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-65.0,  Cytomegalovirus Retinitis HIV Infections   Concurrent Medication Excluded Acyclovir Zidovudine (AZT) Any potentially nephrotoxic agent, especially aminoglycosides, pentamidine, or amphotericin B Prior Medication Excluded Ganciclovir Foscarnet Excluded within 7 days of study entry
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Cytomegalovirus Retinitis HIV Infections Concurrent Medication Allowed Chemotherapy for Kaposi's sarcoma (excluding interferon) if patient is hematologically stable for at least 30 days prior to entry Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC) after first two weeks of study period if absolute neutrophil count is > 1000 cells/mm3 and hemoglobin = or > 8 g/dl Vancomycin Fluconazole or investigational triazoles (e.g., itraconazole, SCH 39304) for disseminated fungal infection Pneumocystis carinii pneumonia prophylaxis (except parenteral pentamidine) Acyclovir or other appropriate medication may be instituted in the event of the appearance of Herpes simplex virus (HSV) or Varicella zoster virus (VZV) infections G-CSF or GM-CSF for grade 4 neutropenia  Co-existing Condition Patients with the following conditions or symptoms are excluded Evidence of tuberculous, diabetic or hypertensive retinopathy Osteomalacia, neoplasm metastatic to bone or other bone disease Any clinically significant pulmonary or neurologic impairment (for example, patients who are intubated or comatose) Retinal detachment Corneal, lens, or vitreous opacification precluding funduscopic exam Concurrent Medication Excluded Immunomodulators, biologic response modifiers or investigational agents not specifically allowed
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-65.0,  Cytomegalovirus Infections HIV Infections Concurrent Medication Allowed Pentamidine aerosol for prophylaxis of recurrent Pneumocystis carinii pneumonia (PCP) in patients currently receiving such treatment Prior Medication Allowed Zidovudine (AZT) but only if patient has been taking the drug for > 6 weeks at a dose = or < 600 mg/day, and had < 10 percent decrease in hematocrit, neutrophils, and platelets in the last 30 days. Those off AZT must have been off it for > 1 month Patients must Have documented cytomegalovirus (CMV) viremia or viruria Have a diagnosis of HIV infection by ELISA or Western blot Be able to participate as an outpatient  Co-existing Condition Patients with the following are excluded HIV wasting syndrome (involuntary weight loss > 10 percent of baseline body weight and/or chronic diarrhea or weakness and documented fever for at least 30 days) Clinical or x-ray evidence of bronchitis, pneumonitis, pulmonary edema, effusion, or suspected active tuberculosis Any unstable medical condition including serious cardiovascular, infectious, oncologic, renal, or hepatic condition Cytomegalovirus end organ disease Kaposi's sarcoma requiring chemotherapy Systemic fungal infection requiring amphotericin therapy Diagnosis of idiopathic thrombocytopenic purpura (persistent platelet counts < 100000 platelets/mm3 for = or > 3 months) Patients with the following are excluded
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Healthy Volunteers ALL Greater than or equal to 18 years old Ability to sign informed consent For women of child-bearing potential, negative result on a serum or urine pregnancy test within 1 week prior to the procedure Willingness to allow storage of blood or biopsy samples for possible future use to study HIV/AIDS, related diseases or the immune system; willingness to permit HLA testing FOR No medical contraindication to tonsillar, lymph node, or intestinal biopsy For tonsillar biopsy, presence of visible tonsillar tissue; for lymph node biopsy, palpable lymph nodes No aspirin or piroxicam (Feldene) for 10 days prior to the procedure; other non steroidal anti-inflammatory drugs (e.g. ibuprofen) must be discontinued the day prior to the procedure. Acetaminophen [Tylenol] is permitted at any time FOR  FOR ALL Platelet count less than 75,000 platelets/mm(3) PT or PTT prolonged by greater than 2 seconds Known underlying bleeding disorder Pregnancy FOR HIV-POSITIVE OR ICL FOR LYMPH NODE Use of narcotics (other than as prescribed by a physician) or cocaine less than 1 week prior to the date of biopsy FOR ALL FOR Use of narcotics (other than as prescribed by a physician) or cocaine less than 1 week prior to the date of biopsy Significant heart valve abnormalities
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atherosclerosis Chlamydia Infections Cytomegalovirus Infections Pneumonia, Bacterial Postmenopause Must be a postmenopausal woman 65 years of age or younger Time since last date of menses should be at least 12 months, with plasma estradiol less than 50 pg/ml and FSH greater than 50 pg/ml Women must be without clinical evidence of CAD as determined by history, cardiovascular physical examination, and EKG Must not have used hormone replacement therapy within past 6 months Must not have used dietary supplements and any medication (over-the-counter or prescribed) within 1 month. Acetaminophen use is allowed Must not have a history of alcoholism or binge-drinking Must not have diabetes mellitus or known abnormal glucose intolerance test Must not have a history of stroke, angina or myocardial infarction Must not have a history of deep venous thrombosis/pulmonary embolism Must not have a history of cancer (except for treated squamous cell and basal cell carcinomas)
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.25-999.0,  Cytomegalovirus Infections Cytomegalovirus Retinitis HIV Infections   Co-existing Condition Patients with the following are excluded Cytomegalovirus (CMV) disease who meet the for a treatment IND protocol, or other clinical studies, including controlled clinical studies of anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered immediately life-threatening Transplant patients in whom trial reduction of immunosuppressive drug treatment is feasible Children with congenital or neonatal CMV where there is not a documented primary or acquired immunodeficiency Hypersensitivity to acyclovir or ganciclovir Receiving antimetabolite treatment that cannot be discontinued Concurrent Medication Excluded
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  HIV Infections Concurrent Medication Allowed All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP) Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry Patients must have Diagnosis of AIDS Weight loss > 10 percent of premorbid body weight First or second episode of acute Pneumocystis carinii pneumonia (PCP)  Co-existing Condition Patients with the following conditions or symptoms are excluded Do Not Resuscitate (DNR) status Biliary stasis Patients with the following are excluded Do Not Resuscitate (DNR) status Biliary stasis Prior Medication Excluded within 3 months of study entry Immunomodulators
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiovascular Diseases Coronary Disease Cerebrovascular Accident Heart Diseases Myocardial Infarction Infection Chlamydia Infections Cytomegalovirus Infections Helicobacter Infections Atherosclerosis
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Cytomegalovirus Infections Cytomegalovirus Retinitis Pneumonia, Pneumocystis Carinii HIV Infections Patients may be eligible if they Are HIV positive (except Group 3b) Are at least 13 years old (consent of parent or guardian required if under 18) Patients may be eligible for Group 1a if they Have acute PCP Have never received potent anti-HIV drugs or have not received potent anti-HIV drugs for at least 8 weeks prior to getting PCP Have a CD4 cell count below 200 cells/mm3 Patients may be eligible for Group 1b if they Have CMV disease Meet 1 of the following requirements: (1) have never received potent anti-HIV drug containing a protease inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI), (2) have not received potent anti-HIV drugs for at least 8 weeks before getting CMV disease, or (3) have been on stable anti-HIV therapy for at least 3 months with no new anti-HIV drugs started before CMV disease returned  Patients will not be eligible if they Have received a vaccine within 14 days of study entry or plan to receive one during the study Have taken GM-CSF, any investigational drugs, or any drugs that might affect the immune system within 30 days of study entry or plan to take 1 of these medications during the study. (Prednisone for patients with PCP and G-CSF is allowed.) Abuse drugs
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cytomegalovirus Infections Age 18-65 CMV seropositive Informed consent given  CMV seronegative Abnormal blood counts (hemoglobin less than 12 g/dl, platelets less than 150,000/ul, absolute neutrophil count less than 1,500/ul, absolute lymphocyte count less than 1,000/ul) Known history of heart, lung, kidney, liver, or bleeding disorder Diagnosis of HIV infection Diagnosis or suspicion of immunodeficiency state History of intravenous drug use Currently pregnant
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pneumonia All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study  Patients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  CMV Disease For Patient Consenting patients with indication for myeloablative BMT or NST with an HLA matching sibling available, for transplant Patients at risk of CMV disease including seronegative patients; patients with seronegative donors, and seronegative donor for sero positive patients Patients with resistant CMV viremia or CMV disease not responding to conventional treatment with ganciclovir, or Foscarnet Patients with HLA phenotype for which a relevant peptide for CMV exists For Donor Consenting sibling >18 years old HLA phenotype for which a relevant peptide for CMV exists  For Patient Patients with severe resistant GVHD where there may be a risk to administer DLI or immunized donor lymphocytes For Donor Consenting sibling >18 years old HLA phenotype for which a relevant peptide for CMV exists Donor with an infectious disease (e.g. HIV-1; HBV, etc.)
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  CMV Disease Viral Resistance Rejection Death Age greater than 18 years 2) WBC greater than 2000/mm3 with ANC greater than 500/mm3 3) Platelet count greater than 50,000/mm3 4) Hematocrit greater than 24 5) Life expectancy greater than 1 year as determined by investigator 6) Females must have a negative pregnancy test and any sexual partner must also agree to practice a barrier and/or hormonal method of birth control while participating in this study and for 90 days after. Females must agree to have a pregnancy test if a menstrual cycle is missed, and if positive, this must be reported  Patients receiving systemic therapy for acute opportunistic infection at time of enrollment Patients receiving investigational drugs Patients with malignancies within the last 5 years with the exception of excised basal or squamous cell skin cancers Patients with active substance abuse or other condition that would impair compliance Patients who are unable to give informed consent Any patient with a creatinine clearance < 40 after delayed graft function and or post-transplant ATN has completely resolved, or the patient is deemed not to have the prospect of any further improvement of creatinine clearance (>40) as would occur with resolving ATN Persistent ANC < 1,000 for 2 consecutive weeks despite treatment with G-CSF Any female patient who plans to become pregnant within one year
Patient description: A 62 yo male presents with four days of non-productive cough and one day of fever. He is on immunosuppressive medications, including prednisone. He is admitted to the hospital, and his work-up includes bronchoscopy with bronchoalveolar lavage (BAL). BAL fluid examination reveals owl's eye inclusion bodies in the nuclei of infection cells.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cytomegalovirus Infections Patients receiving allogeneic peripheral blood stem cell transplant from either a related or unrelated donor at Washington University Medical Center An initial episode of CMV viremia At the time of randomization ANC greater than or equal to 1000 Age greater than or equal to 18 Adequate renal function with creatinine clearance greater than 10 ml/min Total bilirubin less than or equal to 3.0  Current GI graft versus host disease grade III-IV Development of CMV disease prior to or at the time of the first detection of CMV viremia by PCR Uncontrolled emesis or diarrhea (greater than or equal to 4 episodes per day) for 2 consecutive days Pregnant or nursing female patient Known hypersensitivity to ganciclovir